Literature DB >> 17610896

Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization.

Chen Xue Fen1, David W Coomber, David P Lane, Farid J Ghadessy.   

Abstract

The p53 tumour suppressor governs cell fate by differential transactivation of a spectrum of target genes. To further understand how p53 discriminates between target promoters, we have for the first time used in vitro compartmentalization (IVC) to evolve variants with greater affinity for the distal p53 response element in the promoter of the p21 gene involved in cell-cycle arrest, and for the low affinity BS1 response element of the pro-apoptotic PUMA gene. These variants have mutations in the L1 loop of the p53 DNA binding domain and in the N-terminal proline-rich domain. The in vitro binding phenotype of these variants extends to both increased transactivation of promoters containing the response elements in reporter gene studies and increased up-regulation of endogenous p21 as compared to wild-type p53. One variant was co-selected for increased binding to both response elements yet displayed increased apoptotic function. This result supports the notion that prediction of phenotypic outcome based on transcriptional activation of individual genes is confounded by the networked complexity of the p53 response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610896     DOI: 10.1016/j.jmb.2007.05.099

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

Review 1.  The tumor suppressor p53: from structures to drug discovery.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02-10       Impact factor: 10.005

2.  Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing.

Authors:  Bradford C Powell; Lichun Jiang; Donna M Muzny; Lisa R Treviño; Zoann E Dreyer; Louise C Strong; David A Wheeler; Richard A Gibbs; Sharon E Plon
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 3.  Expanding the scope of site-specific recombinases for genetic and metabolic engineering.

Authors:  Thomas Gaj; Shannon J Sirk; Carlos F Barbas
Journal:  Biotechnol Bioeng       Date:  2013-09-13       Impact factor: 4.530

4.  In vitro selection of mutant HDM2 resistant to Nutlin inhibition.

Authors:  Siau Jia Wei; Thomas Joseph; Adelene Y L Sim; Larisa Yurlova; Kourosh Zolghadr; David Lane; Chandra Verma; Farid Ghadessy
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

5.  Induction of nuclear translocation of mutant cytoplasmic p53 by geranylgeranoic acid in a human hepatoma cell line.

Authors:  Chieko Iwao; Yoshihiro Shidoji
Journal:  Sci Rep       Date:  2014-03-24       Impact factor: 4.379

6.  Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.

Authors:  Siau Jia Wei; Sharon Chee; Larisa Yurlova; David Lane; Chandra Verma; Christopher Brown; Farid Ghadessy
Journal:  Oncotarget       Date:  2016-05-31

7.  An efficient method to assemble linear DNA templates for in vitro screening and selection systems.

Authors:  Viktor Stein; Florian Hollfelder
Journal:  Nucleic Acids Res       Date:  2009-07-17       Impact factor: 16.971

8.  Selection of bacteriophage lambda integrases with altered recombination specificity by in vitro compartmentalization.

Authors:  Yvonne Tay; Candice Ho; Peter Droge; Farid J Ghadessy
Journal:  Nucleic Acids Res       Date:  2009-12-04       Impact factor: 16.971

9.  Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics.

Authors:  Suryani Lukman; David P Lane; Chandra S Verma
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.